STOCKHOLM, Sweden — Calliditas Therapeutics (Formerly known as Pharmalink), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in...
Latest News
STOCKHOLM, Sweden — Calliditas Therapeutics (Formerly known as Pharmalink) (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) , announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina...
STOCKHOLM, Sweden — Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that primary safety endpoints of a Phase 2a, randomized, double-blind, placebo-controlled trial of setanaxib in patients with Alport syndrome were presented in a High-Impact Clinical Trials session at the American Society of Nephrology Kidney Week in Houston, Texas, on Saturday,...
OSLO, Norway & BOSTON, Mass. – Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CAL101, its lead clinical candidate currently being evaluated in...
OSLO, Norway & BOSTON, Mass. — Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the first patients have been dosed in the Phase 2 AURORA study of CAL101 for IPF. AURORA is a randomized, double-blind, placebo-controlled trial designed...
LUND, Sweden — Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa®, octreotide subcutaneous depot (CAM2029), for the maintenance treatment in adult patients with acromegaly who have responded to and...
Beijing, China – Most people with schizophrenia have extensive impairment of memory, including prospective memory, which is the ability to remember to perform future activities. Results from a randomized clinical trial published in Neuropsychopharmacology Reports indicate that repetitive transcranial magnetic stimulation (rTMS), a non-invasive method that uses alternating magnetic fields...
SAN FRANCISCO, California — Including transarterial radioembolization with Yttrium-90 (Y90-TARE) as a neoadjuvant treatment for locally advanced intrahepatic cholangiocarcinoma (CCA) may improve survival outcomes and resection rates compared with chemotherapy alone, according to the results of a recent retrospective analysis presented at the 2024 American Society of Clinical Oncology (ASCO)...
Ann Arbor, Mich. – Colorectal cancer screening is widely recommended for adults ages 45 to 75 with an average risk of developing the disease. However, many people don’t realize that the benefits of screening for this type of cancer aren’t always the same for older adults. “While many clinicians simply...
Milwaukee, Wis. – Preeclampsia is a mysterious condition that occurs in about one of 10 pregnancies without any early warning signs. After 20 weeks or more of normal blood pressure during the pregnancy, patients with preeclampsia will begin to experience elevated blood pressure and may also have increased levels of...